Travere Therapeutics, Inc., today announced that the Company will present three abstracts on the effect of FILSPARI (sparsentan) in rare kidney disease at the upcoming International Podocyte ...

Pharmaceutically made cannabidiol targeting myocarditis did not increase cardiovascular events in at-risk patients, a ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱 ®) in combination with ...